TradingView puts its Marketplace-only rule on hold: what changed on 1 November

TradingView's rule that paid invite-only scripts could only be sold through the TradingView Marketplace did not take effect on 1 November 2026. On 27 October the company said that nothing would change on that date for creators or their users, and that it is writing new terms that will let creators keep selling, for example on their own websites or as part of trading courses.

Update, 3 November 2026: As of 3 November, the revised terms have not been published. TradingView's blog has no post about them after the 27 October update, and its Terms of Use still carry the Marketplace-only wording. We will update this post when the new terms appear.

What happened

On 30 September 2026 TradingView announced that commercial scripts were moving to the Marketplace. From 1 November 2026, selling access to invite-only scripts outside the Marketplace would no longer be allowed, including bundling access into another paid product. Customers who had paid before that date would keep access for the period they bought, and vendors who carried on taking payments outside the Marketplace without contacting TradingView would have their scripts blocked.

On 27 October 2026 TradingView changed course in a Marketplace update. It said it is drafting new terms that will allow "selling your indicators on your own website or as part of your trading courses", that "nothing will change on November 1 for you or your users", and that it will publish the updated terms and an FAQ the following week. According to TokenPost (27 October 2026), more than 1,500 script authors had contacted TradingView about the change.

If you read that Marketplace-only sales started on 1 November, that report is out of date. Some coverage still gives 1 November as the start date: a Finance Magnates article dated 27 October says invite-only access could be sold only through the Marketplace "from Sunday, November 1" without mentioning TradingView's update the same day, and an FXStreet video from 1 October predates the change of course. Neither reflects what TradingView has said since.

What is confirmed and what isn't

• Confirmed: 1 November did not change anything for creators or buyers, according to TradingView's 27 October post. The same post said the window for vendors of invite-only indicators to submit requests would close on that date.
• Promised, not yet out: TradingView said it would publish the updated terms and an FAQ the week after 1 November. As of 3 November, the revised terms have not been published, and we could not find the FAQ on TradingView's site either.
• Still in the live terms: as of 3 November, section 23 of TradingView's Terms of Use still says invite-only scripts are for non-commercial use and that scripts for commercial use may only be distributed via the Marketplace. Expect this wording to change when the new terms land.
• Not confirmed: fees. Neither TradingView post mentions a fee or commission, and the live Terms of Use don't either. A figure of $29.95 per user circulating on X is unconfirmed: Finance Magnates notes that TradingView has not confirmed any such fee, and that its Creator Program terms put the platform fee at 0%. In late September sellers on X said they had seen a per-user "Technology Fee" in the terms; Prop Trader Edge (1 October 2026) reports that TradingView later said this was sent in error and would not be implemented, but we could not find a TradingView statement saying so. Don't plan around any number until it appears in the terms.

What it means for algo and systematic traders

For now, an invite-only indicator or strategy you pay for outside the Marketplace should keep working as it did. What the final terms will say about fees, refunds and how outside sales are handled is still unknown, so a long subscription bought today carries more uncertainty than a monthly one.

The bigger question for a buyer is the same as before: does the script have an edge at all? TradingView's own guide to invite-only scripts recommends doing your own research before using one and asking whether the author offers a trial. A trial is only useful if you test something during it.

What to do now

• Buyers: prefer monthly over annual or lifetime plans until the terms are out, and keep a record of what you paid for and when.
• Sellers: read the revised terms as soon as they are published, and don't change your checkout based on reports about fees.
• Test a paid strategy during the trial. If the script is a strategy, it fills the Strategy Tester. Open the Trades tab and download the List of Trades (export depends on your TradingView plan), then check whether the results hold across sessions, weekdays and hours, or come from one narrow slice. Check a few hundred trades rather than a few dozen, and look at the test settings, such as bar detalization and fill assumptions, before you trust the numbers.
• Know what an indicator can't show you. An indicator draws signals but produces no trade list, so there is nothing to export and test. Ask the seller for a strategy version, or treat the claims as untested.

Read more

For a step-by-step method, read how to test an invite-only TradingView strategy before you pay. Our guide to exporting TradingView Strategy Tester results shows where the download button is and what each column means. Before you pay for a script, run through is my backtest overfit? and the backtest validation checklist, and read how bar detalization and fill settings change Strategy Tester results. To see which sessions, weekdays, times and volatility conditions make or lose the money, upload the trade list to the free Entry Analysis report. It works with any supported broker via live sync, platform exports or any spreadsheet through the Custom CSV importer, with no card needed.